Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab
Saved in:
Main Authors: | Efterpi Zafiriou, Emmanouil Karampinis, Vasileios Papadopoulos, Georgia Stefani, Athanasios Kotsakis, George Vassilopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
Mattioli1885
2025-01-01
|
Series: | Dermatology Practical & Conceptual |
Subjects: | |
Online Access: | https://dpcj.org/index.php/dpc/article/view/4642 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
by: Liu J, et al.
Published: (2025-02-01) -
Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
by: Mi-Ae Lyu, et al.
Published: (2025-02-01) -
Ruxolitinib and oHSV combination therapy increases CD4 T cell activity and germinal center B cell populations in murine sarcoma
by: Ravi Dhital, et al.
Published: (2025-03-01) -
Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera
by: Naomi Fei, et al.
Published: (2017-01-01) -
Successful treatment of pyoderma gangrenosum complicated by JAK2V617F mutation-positive myelofibrosis with adalimumab and systemic steroid
by: Kyohei Shibuta, et al.
Published: (2025-01-01)